Skip to content
No picture yet

Welireg 40 mg – DIN 02528908

Welireg is Belzutifan 40 mg (tablet), sold in Canada. It is supplied by Merck Canada Inc. We don't have a photo or description of what this pill looks like yet, so check the name and code on the box or bottle, and ask a pharmacist before taking it. Its official Health Canada listing links to the product monograph, which describes the tablets.

Sold in Canada

Belzutifan 40 mg

Brand
Welireg
Strength
40 mg
Form
Tablet
Manufacturer
Merck Canada Inc
Drug class
Hypoxia-inducible factor inhibitor
Sold in
Canada
DIN
02528908

Source: Health Canada's Drug Product Database. Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Belzutifan pills and guides

What is Belzutifan used for?

Belzutifan is a hypoxia-inducible factor inhibitor.

Medicine type
Hypoxia-inducible factor inhibitor
Official uses from the US prescribing label

von Hippel-Lindau (VHL) disease

WELIREG is indicated for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.

Renal Cell Carcinoma with a Clear Cell Component (ccRCC)

  • WELIREG, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the adjuvant treatment of adult patients with ccRCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
  • WELIREG is indicated for the treatment of adult patients with advanced ccRCC following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).

Pheochromocytoma or Paraganglioma (PPGL)

WELIREG is indicated for the treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL).

From the FDA-approved label on DailyMed (published Jun 29, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your medicine? Check the box

  • The box or bottle shows DIN 02528908.
  • It names Welireg, Belzutifan 40 mg.
  • A loose pill is a different matter: without a description of its markings, a pharmacist has to confirm what it is.

Sold in Canada as Welireg by Merck Canada Inc.

In Canada: prescription only.

Ingredients

Active: Belzutifan

Other Belzutifan pills